The 36-month beta value for CYTK is at 0.64. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 9 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CYTK is 116.79M, and currently, shorts hold a 11.99% of that float. The average trading volume for CYTK on July 09, 2025 was 1.87M shares.
CYTK) stock’s latest price update
The stock price of Cytokinetics Inc (NASDAQ: CYTK) has jumped by 7.15% compared to previous close of $34.25. Despite this, the company has seen a gain of 9.10% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment.
CYTK’s Market Performance
Cytokinetics Inc (CYTK) has seen a 9.10% rise in stock performance for the week, with a 13.62% gain in the past month and a 1.97% surge in the past quarter. The volatility ratio for the week is 4.01%, and the volatility levels for the past 30 days are at 3.95% for CYTK. The simple moving average for the past 20 days is 9.07% for CYTK’s stock, with a -17.24% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Barclays repeating the rating for CYTK by listing it as a “Overweight.” The predicted price for CYTK in the upcoming period, according to Barclays is $55 based on the research report published on April 24, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $86. The rating they have provided for CYTK stocks is “Buy” according to the report published on February 07th, 2025.
Stifel gave a rating of “Buy” to CYTK, setting the target price at $80 in the report published on January 22nd of the current year.
CYTK Trading at 9.75% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.21% of loss for the given period.
Insider Trading
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Inc, sale 2,000 shares at $33.76 during a trade that took place back on Jul 08 ’25, which means that Malik Fady Ibraham is holding 140,610 shares at $67,520 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -29.43 for the present operating margin
- -13.6 for the gross margin
The net margin for Cytokinetics Inc stands at -32.01. The total capital return value is set at -0.51.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 1.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at -2.97. The interest coverage ratio of the stock is -6.14.
Currently, EBITDA for the company is -493.48 million with net debt to EBITDA at -1.39. When we switch over and look at the enterprise to sales, we see a ratio of 264.31. The receivables turnover for the company is 9.55for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.99.
Conclusion
In conclusion, Cytokinetics Inc (CYTK) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
